Valvulopathies

The 2025 ESC/EACTS update redefines the boundaries between surgery and transcatheter therapy. It advocates earlier intervention in severe aortic stenosis, lowers the age threshold for TAVI to 70 years, expands the use of MitraClip to lower-risk scenarios, promotes percutaneous tricuspid treatment, and grants a new central role to advanced imaging in decision-making.

This national study compares the efficiency of robotic-assisted versus conventional mitral valve repair in the United States, stratifying centers by surgical volume and experience.

This observational, retrospective study includes data from two Italian centers, assessing in-hospital mortality and long-term survival in sexagenarians undergoing one of two procedures: aortic root and valve replacement using a valved conduit versus valve-sparing aortic root replacement (VSRR) using the reimplantation technique.

Prospective observational study evaluating 5-year clinical outcomes of transcarotid TAVR in moderate-to-high surgical risk patients with no viable femoral access.

This retrospective observational study evaluated 2250 patients who underwent TAVI, comparing outcomes based on the presence or absence of significant (moderate or greater) concomitant mitral regurgitation (MR).

Commentary on a reanalysis of the 4-year results from the Evolut Low Risk trial, excluding Abbott/St. Jude Trifecta prostheses from the surgical cohort.

This summary updates the indications for intervention in aortic regurgitation (AR) according to the 2021 ESC/EACTS guidelines, with a practical and clinically oriented perspective.

The international multicenter CUTTING-EDGE registry investigates surgical strategies and outcomes in patients undergoing conventional surgery after failed mitral transcatheter edge-to-edge repair (M-TEER).

This retrospective observational study, based on real-world data, aimed to assess the 10-year outcomes of the St. Jude/Abbott Epic® porcine mitral valve.